Mor E - Search Results

1

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.

Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, Mor E, Bodian C, Guy SR, Schwartz ME, Emre S, Bodenheimer HC Jr, Miller CM. Sheiner PA, et al. Among authors: mor e. Hepatology. 1998 Sep;28(3):831-8. doi: 10.1002/hep.510280334. Hepatology. 1998. PMID: 9731580 Clinical Trial.

2

Liver transplantation at Mount Sinai Hospital.

Mor E, Sheiner PA, Schwartz ME, Emre S, Guy S, Sung M, Bodenheimer H, Berk P, Miller CM. Mor E, et al. Clin Transpl. 1994:173-80. Clin Transpl. 1994. PMID: 7547536

3

High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation.

Mor E, Meyers BR, Yagmur O, Kishikawa K, Sheiner PA, Emre S, Schwartz ME, Miller CM. Mor E, et al. Transpl Int. 1995;8(2):152-6. doi: 10.1007/BF00344426. Transpl Int. 1995. PMID: 7766298

4

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.

Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, Kolesnikov V, Bodenheimer H, Emre S, Miller CM. Sheiner PA, et al. Among authors: mor e. Hepatology. 1995 Jan;21(1):30-4. Hepatology. 1995. PMID: 7806166

5

Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature.

Hytiroglou P, Theise ND, Schwartz M, Mor E, Miller C, Thung SN. Hytiroglou P, et al. Among authors: mor e. Hepatology. 1995 Mar;21(3):703-8. Hepatology. 1995. PMID: 7875667

6

Neurologic complications of orthotopic liver transplantation.

Bronster DJ, Emre S, Mor E, Sheiner P, Miller CM, Schwartz ME. Bronster DJ, et al. Among authors: mor e. Mt Sinai J Med. 1994 Jan;61(1):63-9. Mt Sinai J Med. 1994. PMID: 8183296 Review.

7

Use of hepatitis C-positive donors in liver transplantation.

Sheiner PA, Mor E, Schwartz ME, Miller CM. Sheiner PA, et al. Among authors: mor e. Transplant Proc. 1993 Dec;25(6):3071. Transplant Proc. 1993. PMID: 8266456 No abstract available.

8

Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506.

Jindal RM, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, Mor E, Sheiner P, Miller CM. Jindal RM, et al. Among authors: mor e. Transplantation. 1994 May 15;57(9):1395-8. doi: 10.1097/00007890-199405150-00020. Transplantation. 1994. PMID: 7514317 Clinical Trial. No abstract available.

9

Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression.

Mor E, Sheiner PA, Schwartz ME, Emre S, Guy S, Miller CM. Mor E, et al. Transplantation. 1994 Aug 15;58(3):380-2. Transplantation. 1994. PMID: 7519800 No abstract available.

10

Gastrointestinal toxicity associated with FK 506 in liver transplant recipients.

Fisher A, Schwartz M, Mor E, Sheiner P, Emre S, Guy S, Miller C. Fisher A, et al. Among authors: mor e. Transplant Proc. 1994 Dec;26(6):3106-7. Transplant Proc. 1994. PMID: 7527947 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

348 results

Search Page

Filters